TH-302, or What I learned by reading The Motley Fool

As I’ve mentioned before, my husband has extrahepatic CCA or possibly pancreatic cancer. Pathologists and his doctors have been unable to make a final diagnosis. We can’t see any tumors on his CT scans, only enlarged lymph nodes. Because of this, his doctor frequently looks for treatments and trials for pancreatic cancer. Right now, my husband is receiving gemzar and Abraxane, and it’s working pretty well. However, we don’t have our next option lined up. His oncologist would like to try a targeted therapy, and in particular would love to get us into a B-Raf trial but hasn’t been able to find one that is currently recruiting for either type of cancer.

I hate not having a good plan, so I’ve been searching, too. Tonight, I stumbled on this fascinating article for investors about pancreatic cancer research and which drugs have the potential to blow the disease out of the water (and make a ton of $).
http://www.fool.com/investing/general/2013/05/25/tackling-cancer-pancreatic-cancers-biggest-current.aspx
I was happy to see Abraxane listed as a top choice, but I had never heard of TH-302. There is a trial near us in New England, so we are going to ask our onc what he thinks about it as a potential next step. Wondering if any of the experts on this board have heard of TH-302 and its potential for helping CCA? Thanks so much!